HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a ...
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...
For those of us diagnosed with a rare disease, the Orphan Drug Act of 1982 has been a lighthouse of hope for a perilous journey. The ODA recognized the lethal ...